RESUMO
En bloc resection is essential for accurate pathological evaluation in patients with superficial esophageal squamous cell carcinoma (SESCC). This retrospective study aimed to clarify optimal treatment selection of endoscopic resection according to lesion size. A total of 760 patients underwent endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) between January 2011 and December 2015. Among them, this retrospective study included 196 solitary index SESCC lesions ≤20 mm, with the deepest invasion to the mucosa or superficial submucosa endoscopically. The lesions were classified according to size measured via endoscopy as follows; group A: lesions ≤10 mm, group B: lesions ≥11 mm but ≤15 mm, and group C: lesions ≥16 mm but ≤20 mm. The short- and long-term outcomes were investigated for EMR and ESD subgroups. In patients undergoing EMR and ESD, en bloc resection rates for group A and B were not different (98.8 vs. 100%, 93.3 vs. 100%, respectively). However, the en bloc resection rate was significantly lower in EMR than that in ESD for group C (64.3 vs. 100%, P < 0.001). Furthermore, the use of adjunctive ablative therapy rate was significantly higher in EMR than that in ESD in group C (35.7 vs. 0%, P < 0.001). The 5-year cumulative local recurrence rate of group C was significantly higher than that of group A + B after EMR (P < 0.01). EMR was an adequate treatment for SESCC lesions ≤15 mm. On the other hand, ESD could be necessary to achieve en bloc resection for lesions ≥16 mm to avoid local recurrence.
Assuntos
Ressecção Endoscópica de Mucosa , Neoplasias Esofágicas , Carcinoma de Células Escamosas do Esôfago , Neoplasias Esofágicas/cirurgia , Carcinoma de Células Escamosas do Esôfago/cirurgia , Humanos , Recidiva Local de Neoplasia , Estudos Retrospectivos , Resultado do TratamentoRESUMO
BACKGROUND: Developed as a biological response modifier (BRM), lentinan mitigates patients' symptoms by boosting the immune system. In combination with S-1 (tegafur, gimeracil, oteracil), lentinan is reported to mitigate adverse reactions to therapy for unresectable recurrent gastric cancer and prolong survival. However, there are few reports from actual clinical practice, and precise methods of using lentinan have not yet been established. This study retrospectively examined the usefulness of lentinan in patients. PATIENTS AND METHODS: The subjects of this study were 39 patients who were diagnosed with unresectable gastric cancer, based on preoperative examinations or findings at laparotomy in our Department. These patients underwent S-1/paclitaxel therapy. Nineteen of the patients received lentinan while 20 did not, and these two groups of patients were compared. RESULTS: There were no significant differences in patients' characteristics such as the male:female ratio, age at the start of chemotherapy, and staging classification of the 19 patients receiving lentinan and the 20 patients not receiving lentinan. Comparison of the two groups revealed no significant differences in overall survival time, but comparison of the duration of therapy revealed that therapy tended to be longer for the group taking lentinan than the group not taking lentinan. Adverse events were noted in 61.5% (24 patients) of the total patients group; such events tended to occur less frequently in the group receiving lentinan. CONCLUSION: Lentinan inclusion in therapy did not seem to prolong survival. Nevertheless, the duration of therapy tended to be longer for patients taking lentinan. This may be due to the fact that adverse events tended to occur less frequently in these patients during therapy. A decline in the incidence of adverse events increases the duration of therapy and improves the patients' quality of life (QOL); it may also prolong survival. Optimal methods of using lentinan need to be established.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Lentinano/administração & dosagem , Neoplasias Gástricas/tratamento farmacológico , Combinação de Medicamentos , Feminino , Humanos , Estimativa de Kaplan-Meier , Lentinano/efeitos adversos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Ácido Oxônico/administração & dosagem , Ácido Oxônico/efeitos adversos , Paclitaxel/administração & dosagem , Paclitaxel/efeitos adversos , Estudos Retrospectivos , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/patologia , Tegafur/administração & dosagem , Tegafur/efeitos adversosRESUMO
BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated. Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required. This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy. PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study. Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded. There were 8 cases of jejunal or ileal cancer treated during the study period. The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence. RESULTS: The male:female ratio of the 8 patients was 6:2, the mean age at surgery was 59.7±15.9 (35-76) years, and the mean postoperative follow-up was 41.1±48.0 (7-152) months. Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each. The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm. TNM staging indicated that 3 tumors were stage II, 1 was stage III, and 4 were stage IV. Six patients underwent postoperative chemotherapy. One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of. The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD). Three out of the four patients with PD died. CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection. Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs. Nevertheless, there is no established regimen for such chemotherapy. Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success. Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report. The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen. Compiling and studying such cases are crucial to accomplishing that goal.
Assuntos
Neoplasias Intestinais/tratamento farmacológico , Intestino Delgado/patologia , Adulto , Idoso , Terapia Combinada , Feminino , Humanos , Neoplasias Intestinais/patologia , Neoplasias Intestinais/cirurgia , Masculino , Pessoa de Meia-IdadeRESUMO
A 50-year-old man was admitted because of right lateral abdominal pain, easy fatigue and anemia. An endoscopic examination revealed advanced ascending colon cancer, and abdominal CT scan demonstrated enlarged metastatic lymph nodes of superior mesenteric arterial circumference. The Serum CEA rose considerably. The preoperative diagnosis was cStage IV (SS, N(4), P(0), H(0), M(-)), and right colectomy was performed on March 2, 2005. The metastatic lymph nodes around the superior mesenteric arterial root macroscopically remained. From the 20th postoperative day, we started combination chemotherapy using S-1 plus CPT-11 as one course for three weeks. S-1 (120 mg/body/day) was orally administered for 2 weeks continuously, and CPT-11 (80 mg/m(2)) was done intravenously on day 1 and 8. Serum CEA was normalized in the middle of 3 courses. Moreover, after 13 courses, a complete response (CR) was noted on the follow-up abdominal CT scan. No severe side effect more than grade 2 was observed, there was no interruption of the dosage, and PS was sufficiently maintained kept enough through this combination chemotherapy. The course has been without metastasis, recurrence and a rise of serum CEA now in the 16th postoperative month. S-1/CPT-11 combination chemotherapy is a promising and effective cure for unresectable progressive recurrent colorectal cancer in future.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Colo Ascendente , Neoplasias do Colo/tratamento farmacológico , Neoplasias do Colo/patologia , Linfonodos/patologia , Camptotecina/administração & dosagem , Camptotecina/análogos & derivados , Colectomia/métodos , Neoplasias do Colo/cirurgia , Terapia Combinada , Esquema de Medicação , Combinação de Medicamentos , Humanos , Irinotecano , Metástase Linfática , Masculino , Artéria Mesentérica Superior , Pessoa de Meia-Idade , Ácido Oxônico/administração & dosagem , Indução de Remissão , Tegafur/administração & dosagemRESUMO
Telomere-mimic carbocyclic 5'-nor 3'-deoxyoligonucleotide was synthesized. And it's selectivity to RNA was shown.